We are analyzing https://link.springer.com/article/10.1007/s00223-008-9175-9.

Title:
The Peroxisome Proliferator Activator Receptor Alpha/Delta Agonists Linoleic Acid and Bezafibrate Upregulate Osteoblast Differentiation and Induce Periosteal Bone Formation In Vivo | Calcified Tissue International
Description:
We showed previously that some actions of prostaglandin E2 (PGE2) on bone are caused by its degradation product, PGA2, which mediates its effects via a class of nuclear receptors known as the peroxisome proliferator activator receptors (PPARs), suggesting that the PPARs may be involved in the regulation of bone formation. The aims of this study were to determine the effects of PPARα/δ agonists on bone in vitro and in vivo. PPAR agonists were examined in vitro using the fibroblastic colony-forming unit (CFU-f) assay. The PPARα/δ agonists linoleic acid (LA) and bezafibrate (Bez) were then administered to intact male rats by daily s.c. injection for 12 weeks with either vehicle (10% dimethyl sulfoxide), LA (0.3 mg/kg), or Bez (1 mg/kg). CFU-f assays were performed on stromal cells ex vivo. Bone mineral density (BMD) and serum markers of formation and resorption were measured. Bone histomorphometry was performed at cancellous and cortical bone sites. PPARα/δ agonists increased significantly the number of osteoblastic colonies as demonstrated by increased alkaline phosphatase activity, collagen production, and calcification. This increase was typically equal to or greater than that achieved with the known bone anabolic agent PGE2. In intact male rats, LA and Bez increased metaphyseal BMD by 7% and 11%, respectively. Increased BMD was associated with an increase in total bone area, although no changes were observed in bone formation rate within the trabecular compartment. Serum osteocalcin and osteoprogenitor numbers were increased, whereas there was no change in either tartrate-resistant acid phosphatase 5b or osteoclast number. Both LA and Bez increased cortical bone area by approximately 38%, periosteal perimeter by 15%, and periosteal bone formation by 221% and 140%, respectively. There was no effect on medullary cavity area or endocortical perimeter. These data suggest that PPARα/δ may have roles in bone anabolism, specifically in the regulation of periosteal bone formation. They are potential therapeutic targets for osteoporosis therapy.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Social Networks

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure if the website is profiting.

Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

bone, article, pubmed, google, scholar, cas, formation, peroxisome, receptor, agonists, receptors, rats, tissue, acid, cells, increased, access, proliferatoractivated, privacy, cookies, content, journal, periosteal, prostaglandin, effects, scutt, data, area, publish, research, search, proliferator, activator, differentiation, vivo, october, nuclear, regulation, pparαδ, cfuf, bez, male, marrow, calcif, int, information, log, linoleic, bezafibrate, karen,

Topics {✒️}

peroxisome proliferator-activated receptors peroxisome proliferator–activated receptors mineralizing fibroblast-colony-forming assays month download article/chapter fibroblastic colony-forming unit transcription factor pgc-1α pparalpha-leukotriene b4 pathway modeling-dependent bone gain retinoic acid receptor long-term daily administration nuclear receptor signaling pparα/δ agonists related subjects full article pdf privacy choices/manage cookies periosteal bone formation bone formation rate total bone area nuclear receptor ppar agonists polyunsaturated fatty acids cortical bone sites ppar delta bone mineral density cancellous bone site low bone turnover european economic area medullary cavity area bone marrow cells potential therapeutic targets ke hz closed growth plate mc3t3-e1 preosteoblasts antidiabetic compound rosiglitazone journal finder publish conditions privacy policy osteoporosis therapy royal pharmaceutical society young rats increases nuclear receptors intact male rats aged male rats adult stem cells accepting optional cookies article log author information authors sheffield/sheffield children pparα/δ inflammation control check access

Schema {🗺️}

WebPage:
      mainEntity:
         headline:The Peroxisome Proliferator Activator Receptor Alpha/Delta Agonists Linoleic Acid and Bezafibrate Upregulate Osteoblast Differentiation and Induce Periosteal Bone Formation In Vivo
         description:We showed previously that some actions of prostaglandin E2 (PGE2) on bone are caused by its degradation product, PGA2, which mediates its effects via a class of nuclear receptors known as the peroxisome proliferator activator receptors (PPARs), suggesting that the PPARs may be involved in the regulation of bone formation. The aims of this study were to determine the effects of PPARα/δ agonists on bone in vitro and in vivo. PPAR agonists were examined in vitro using the fibroblastic colony-forming unit (CFU-f) assay. The PPARα/δ agonists linoleic acid (LA) and bezafibrate (Bez) were then administered to intact male rats by daily s.c. injection for 12 weeks with either vehicle (10% dimethyl sulfoxide), LA (0.3 mg/kg), or Bez (1 mg/kg). CFU-f assays were performed on stromal cells ex vivo. Bone mineral density (BMD) and serum markers of formation and resorption were measured. Bone histomorphometry was performed at cancellous and cortical bone sites. PPARα/δ agonists increased significantly the number of osteoblastic colonies as demonstrated by increased alkaline phosphatase activity, collagen production, and calcification. This increase was typically equal to or greater than that achieved with the known bone anabolic agent PGE2. In intact male rats, LA and Bez increased metaphyseal BMD by 7% and 11%, respectively. Increased BMD was associated with an increase in total bone area, although no changes were observed in bone formation rate within the trabecular compartment. Serum osteocalcin and osteoprogenitor numbers were increased, whereas there was no change in either tartrate-resistant acid phosphatase 5b or osteoclast number. Both LA and Bez increased cortical bone area by approximately 38%, periosteal perimeter by 15%, and periosteal bone formation by 221% and 140%, respectively. There was no effect on medullary cavity area or endocortical perimeter. These data suggest that PPARα/δ may have roles in bone anabolism, specifically in the regulation of periosteal bone formation. They are potential therapeutic targets for osteoporosis therapy.
         datePublished:2008-10-04T00:00:00Z
         dateModified:2008-10-04T00:00:00Z
         pageStart:285
         pageEnd:292
         sameAs:https://doi.org/10.1007/s00223-008-9175-9
         keywords:
            Peroxisome proliferator activator receptor
            Bone formation
            Osteoporosis
            Periosteum
            Biochemistry
            general
            Endocrinology
            Orthopedics
            Cell Biology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00223-008-9175-9/MediaObjects/223_2008_9175_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00223-008-9175-9/MediaObjects/223_2008_9175_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00223-008-9175-9/MediaObjects/223_2008_9175_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00223-008-9175-9/MediaObjects/223_2008_9175_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00223-008-9175-9/MediaObjects/223_2008_9175_Fig5_HTML.gif
         isPartOf:
            name:Calcified Tissue International
            issn:
               1432-0827
               0171-967X
            volumeNumber:83
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Karen Still
               affiliation:
                     name:University of Sheffield/Sheffield Children’s Hospital
                     address:
                        name:Academic Unit of Child Health, University of Sheffield/Sheffield Children’s Hospital, Sheffield, UK
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Peter Grabowski
               affiliation:
                     name:University of Sheffield/Sheffield Children’s Hospital
                     address:
                        name:Academic Unit of Child Health, University of Sheffield/Sheffield Children’s Hospital, Sheffield, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ian Mackie
               affiliation:
                     name:University of Sheffield/Sheffield Children’s Hospital
                     address:
                        name:Academic Unit of Child Health, University of Sheffield/Sheffield Children’s Hospital, Sheffield, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Mark Perry
               affiliation:
                     name:University of Bristol
                     address:
                        name:Department of Anatomy, University of Bristol, Bristol, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Nick Bishop
               affiliation:
                     name:University of Sheffield/Sheffield Children’s Hospital
                     address:
                        name:Academic Unit of Child Health, University of Sheffield/Sheffield Children’s Hospital, Sheffield, UK
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:The Peroxisome Proliferator Activator Receptor Alpha/Delta Agonists Linoleic Acid and Bezafibrate Upregulate Osteoblast Differentiation and Induce Periosteal Bone Formation In Vivo
      description:We showed previously that some actions of prostaglandin E2 (PGE2) on bone are caused by its degradation product, PGA2, which mediates its effects via a class of nuclear receptors known as the peroxisome proliferator activator receptors (PPARs), suggesting that the PPARs may be involved in the regulation of bone formation. The aims of this study were to determine the effects of PPARα/δ agonists on bone in vitro and in vivo. PPAR agonists were examined in vitro using the fibroblastic colony-forming unit (CFU-f) assay. The PPARα/δ agonists linoleic acid (LA) and bezafibrate (Bez) were then administered to intact male rats by daily s.c. injection for 12 weeks with either vehicle (10% dimethyl sulfoxide), LA (0.3 mg/kg), or Bez (1 mg/kg). CFU-f assays were performed on stromal cells ex vivo. Bone mineral density (BMD) and serum markers of formation and resorption were measured. Bone histomorphometry was performed at cancellous and cortical bone sites. PPARα/δ agonists increased significantly the number of osteoblastic colonies as demonstrated by increased alkaline phosphatase activity, collagen production, and calcification. This increase was typically equal to or greater than that achieved with the known bone anabolic agent PGE2. In intact male rats, LA and Bez increased metaphyseal BMD by 7% and 11%, respectively. Increased BMD was associated with an increase in total bone area, although no changes were observed in bone formation rate within the trabecular compartment. Serum osteocalcin and osteoprogenitor numbers were increased, whereas there was no change in either tartrate-resistant acid phosphatase 5b or osteoclast number. Both LA and Bez increased cortical bone area by approximately 38%, periosteal perimeter by 15%, and periosteal bone formation by 221% and 140%, respectively. There was no effect on medullary cavity area or endocortical perimeter. These data suggest that PPARα/δ may have roles in bone anabolism, specifically in the regulation of periosteal bone formation. They are potential therapeutic targets for osteoporosis therapy.
      datePublished:2008-10-04T00:00:00Z
      dateModified:2008-10-04T00:00:00Z
      pageStart:285
      pageEnd:292
      sameAs:https://doi.org/10.1007/s00223-008-9175-9
      keywords:
         Peroxisome proliferator activator receptor
         Bone formation
         Osteoporosis
         Periosteum
         Biochemistry
         general
         Endocrinology
         Orthopedics
         Cell Biology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00223-008-9175-9/MediaObjects/223_2008_9175_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00223-008-9175-9/MediaObjects/223_2008_9175_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00223-008-9175-9/MediaObjects/223_2008_9175_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00223-008-9175-9/MediaObjects/223_2008_9175_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00223-008-9175-9/MediaObjects/223_2008_9175_Fig5_HTML.gif
      isPartOf:
         name:Calcified Tissue International
         issn:
            1432-0827
            0171-967X
         volumeNumber:83
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Karen Still
            affiliation:
                  name:University of Sheffield/Sheffield Children’s Hospital
                  address:
                     name:Academic Unit of Child Health, University of Sheffield/Sheffield Children’s Hospital, Sheffield, UK
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Peter Grabowski
            affiliation:
                  name:University of Sheffield/Sheffield Children’s Hospital
                  address:
                     name:Academic Unit of Child Health, University of Sheffield/Sheffield Children’s Hospital, Sheffield, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ian Mackie
            affiliation:
                  name:University of Sheffield/Sheffield Children’s Hospital
                  address:
                     name:Academic Unit of Child Health, University of Sheffield/Sheffield Children’s Hospital, Sheffield, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Mark Perry
            affiliation:
                  name:University of Bristol
                  address:
                     name:Department of Anatomy, University of Bristol, Bristol, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Nick Bishop
            affiliation:
                  name:University of Sheffield/Sheffield Children’s Hospital
                  address:
                     name:Academic Unit of Child Health, University of Sheffield/Sheffield Children’s Hospital, Sheffield, UK
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Calcified Tissue International
      issn:
         1432-0827
         0171-967X
      volumeNumber:83
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Sheffield/Sheffield Children’s Hospital
      address:
         name:Academic Unit of Child Health, University of Sheffield/Sheffield Children’s Hospital, Sheffield, UK
         type:PostalAddress
      name:University of Sheffield/Sheffield Children’s Hospital
      address:
         name:Academic Unit of Child Health, University of Sheffield/Sheffield Children’s Hospital, Sheffield, UK
         type:PostalAddress
      name:University of Sheffield/Sheffield Children’s Hospital
      address:
         name:Academic Unit of Child Health, University of Sheffield/Sheffield Children’s Hospital, Sheffield, UK
         type:PostalAddress
      name:University of Bristol
      address:
         name:Department of Anatomy, University of Bristol, Bristol, UK
         type:PostalAddress
      name:University of Sheffield/Sheffield Children’s Hospital
      address:
         name:Academic Unit of Child Health, University of Sheffield/Sheffield Children’s Hospital, Sheffield, UK
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Karen Still
      affiliation:
            name:University of Sheffield/Sheffield Children’s Hospital
            address:
               name:Academic Unit of Child Health, University of Sheffield/Sheffield Children’s Hospital, Sheffield, UK
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Peter Grabowski
      affiliation:
            name:University of Sheffield/Sheffield Children’s Hospital
            address:
               name:Academic Unit of Child Health, University of Sheffield/Sheffield Children’s Hospital, Sheffield, UK
               type:PostalAddress
            type:Organization
      name:Ian Mackie
      affiliation:
            name:University of Sheffield/Sheffield Children’s Hospital
            address:
               name:Academic Unit of Child Health, University of Sheffield/Sheffield Children’s Hospital, Sheffield, UK
               type:PostalAddress
            type:Organization
      name:Mark Perry
      affiliation:
            name:University of Bristol
            address:
               name:Department of Anatomy, University of Bristol, Bristol, UK
               type:PostalAddress
            type:Organization
      name:Nick Bishop
      affiliation:
            name:University of Sheffield/Sheffield Children’s Hospital
            address:
               name:Academic Unit of Child Health, University of Sheffield/Sheffield Children’s Hospital, Sheffield, UK
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Academic Unit of Child Health, University of Sheffield/Sheffield Children’s Hospital, Sheffield, UK
      name:Academic Unit of Child Health, University of Sheffield/Sheffield Children’s Hospital, Sheffield, UK
      name:Academic Unit of Child Health, University of Sheffield/Sheffield Children’s Hospital, Sheffield, UK
      name:Department of Anatomy, University of Bristol, Bristol, UK
      name:Academic Unit of Child Health, University of Sheffield/Sheffield Children’s Hospital, Sheffield, UK
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(101)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.2s.

LINK . SPRINGER . COM {}